4D Molecular Therapeutics (FDMT) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is FDMT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

4D Molecular Therapeutics, Inc. ( FDMT ) Stifel 2026 Healthcare Conference 2026 November 11, 2026 8:00 AM EST Company Participants Christopher Simms - Chief Commercial & Business Officer Kristian Humer - CFO and Principa…

EMERYVILLE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with pot…

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.01 per share a year ago.…

Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, respect…

4D Molecular Therapeutics, Inc. (FDMT) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript…

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are covering the stock, Marketbeat.com reports. One rese…

EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with pot…

4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

4D Molecular Therapeutics NASDAQ: FDMT used its first Investor Day to outline its development and commercial plans for 4D-150, an investigational intravitreal gene therapy for wet age-related macular degeneration, or wet…

4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript…

GeoVax Labs (NASDAQ: GOVX - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses b…

EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with pot…

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) has received an average rating of "Moderate Buy" from the twelve brokerages that are covering the company, MarketBeat Ratings reports. One research analyst…

Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.…

4D Molecular Therapeutics remains a 'Buy' as its gene therapy 4D-150 advances in phase 3 trials for wet AMD and diabetic macular edema [DME]. Topline data from the pivotal 4FRONT-1 and 4FRONT-2 wet AMD studies are expect…

EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with po…

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the firm's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $13.65,…

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One an…

4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript…

4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with po…

EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with pot…

Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) by 17.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The…

Deutsche Bank AG acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired …

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report)'s share price reached a new 52-week high on Tuesday. The company traded as high as $15.03 and last traded at $14.55, with a volume of 3444983 shares. The s…
No recent releases where the company itself is speaking.
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

